Cocrystal Pharma Announces Participation in Virtual Investor Events
January 26 2023 - 8:00AM
Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the participation
of James Martin, co-CEO and CFO, in the following virtual
investment community events:
- Noble Capital
Markets’ J.P. Morgan Healthcare
Conference Takeaways hosted by ChannelChek featuring an
interview with Noble Capital Market’s managing director and senior
biotechnology analyst Robert LeBoyer discussing management’s
perspective on the market environment for biotechnology companies
and Cocrystal’s opportunity. The Takeaways event is available
beginning today, January 26, at 11:00 a.m. Eastern time. Register
here for the event.
- Noble Capital
Markets C-Suite Interview Series hosted by
ChannelChek featuring an interview with Mr. LeBoyer with an update
on Cocrystal’s influenza and COVID-19 antiviral programs and
upcoming clinical and regulatory milestones. The interview will be
available by February 1 on the ChannelChek platform by registering
here.
-
Sequire’s
Virtual Biotechnology Conference featuring a
company presentation on Thursday, February 2 at 11:30 a.m. Eastern
time Eastern time. Register here for the presentation.
About
ChannelChekChannelchek.com is a comprehensive
investor-centric portal featuring more than 6,000 emerging growth
companies that provides advanced market data, independent research,
balanced news, video webcasts, exclusive c-suite interviews, and
access to virtual road shows. The site is available to the public.
Research on Channelchek is provided by Noble Capital Markets, Inc.,
an SEC / FINRA registered broker-dealer since 1984. More
information is available at www.channelchek.com.
About
SequireSequire is a premier investor intelligence
and communications platform where companies can track their
investors’ behaviors and trends and use those insights to engage
current and potential investors across marketing channels. More
information is available at srax.com and mysequire.com.
About Cocrystal Pharma,
Inc.Cocrystal Pharma, Inc. is a clinical-stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication process of influenza
viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses
and noroviruses. Cocrystal employs unique structure-based
technologies and Nobel Prize-winning expertise to create first- and
best-in-class antiviral drugs. For further information about
Cocrystal, please visit www.cocrystalpharma.com.
Investor Contact:LHA Investor RelationsJody
Cain310-691-7100jcain@lhai.com
Media Contact:JQA PartnersJules
Abraham917-885-7378Jabraham@jqapartners.com
# # #
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Apr 2023 to Apr 2024